[Thromboprophylaxis with low-molecular-weight heparin insufficient in high-risk pregnancy]
- PMID: 21527059
[Thromboprophylaxis with low-molecular-weight heparin insufficient in high-risk pregnancy]
Abstract
Objective: To evaluate the efficacy and safety of thromboprophylaxis with a low of low-molecular-weight heparin (LMWH) in women with an intermediate to high risk of pregnancy-related venous thromboembolism (VTE).
Design: Retrospective cohort study.
Methods: We collected data from all pregnant women with an intermediate or high risk of VTE in the period 1996-2009. In accordance with protocol, pregnant women with an intermediate risk of VTE were treated with a prophylactic dose of LMWH for 6 weeks post partum, and pregnant women with a high risk were treated with a prophylactic dose of LMWH during the pregnancy and for 6 weeks post partum. Efficacy was defined as the incidence of VTE during pregnancy or < 3 months post partum, and safety as the incidence of post-partum haemorrhage (PPH) (> 500 ml blood loss) or severe PPH (> 1,000 ml blood loss).
Results: We analysed 34 women (44 pregnancies) with an intermediate risk and 57 women (82 pregnancies) with a high risk of VTE. The incidence of pregnancy-related VTE despite thromboprophylaxis was 5.5% (95% CI: 2.4-12.3). All VTEs occurred in high-risk women, and risk was higher post partum than ante partum: 7.0% (95% CI: 2.9-16.7) and 1.8% (95% CI: 0.4-9.2%), respectively. The risk of PPH was 21.6% (95% CI: 14.3-31.3) and of severe PPH 9.1% (95% CI: 4.7-16.9) and was comparable in women who used LMWH during pregnancy and those who started LMWH post partum.
Conclusion: There was a considerable risk of pregnancy-related VTE in high-risk women despite a prophylactic dose of LMWH during pregnancy and in the post partum period. For these women thromboprophylaxis with a low, prophylactic dose of LMWH appeared to be insufficient.
Comment in
-
[Thromboprophylaxis in pregnant women should be individually tailored].Ned Tijdschr Geneeskd. 2011;155(18):A3568. Ned Tijdschr Geneeskd. 2011. PMID: 21557830 Dutch.
Similar articles
-
Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective?J Thromb Haemost. 2011 Mar;9(3):473-80. doi: 10.1111/j.1538-7836.2011.04186.x. J Thromb Haemost. 2011. PMID: 21232006
-
The incidence and risk factors of recurrent venous thromboembolism during pregnancy.Thromb Res. 2014 Aug;134(2):240-5. doi: 10.1016/j.thromres.2014.04.026. Epub 2014 May 2. Thromb Res. 2014. PMID: 24835671
-
The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy.Thromb Res. 2012 Sep;130(3):334-8. doi: 10.1016/j.thromres.2012.03.007. Epub 2012 Apr 3. Thromb Res. 2012. PMID: 22475315
-
Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis.J Matern Fetal Neonatal Med. 2019 Jun;32(11):1893-1900. doi: 10.1080/14767058.2017.1419179. Epub 2018 Jan 5. J Matern Fetal Neonatal Med. 2019. PMID: 29251025
-
The prevention of pregnancy-related venous thromboembolism.Br J Haematol. 2015 Jan;168(2):163-74. doi: 10.1111/bjh.13159. Epub 2014 Oct 14. Br J Haematol. 2015. PMID: 25312482 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical